Quantum BioPharma announces through its subsidiary, Huge Biopharma Australia, the submission of its patented candidate breakthrough drug, Lucid-21-302, to the Innovative Licensing and Access Pathway Passport program in the United Kingdom. The ILAP Passport application was submitted for Lucid-21-302 as a new, first-in-class treatment for multiple sclerosis.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Announces Private Placement to Bolster Financial Position
- Quantum BioPharma’s Unbuzzd Wellness Launches $5 Million Capital Raise
- Quantum licensee Unbuzzd Wellness launches $5M Reg D capital raise
- Quantum BioPharma and MGH Launch MS Study with Novel Imaging Technique
- Quantum Group announces first person with MS scanned in joint study